公司概述
Bristol-Myers Squibb Company functions as a global biopharmaceutical entity dedicated to the discovery, development, licensing, manufacturing, marketing, distribution, and sale of therapeutic products. The company operates within the Healthcare sector, specifically categorized under the Drug Manufacturers - General industry, which implies a focus on creating essential pharmaceuticals rather than consumer goods or medical devices. Its operational scale is substantial, characterized by a market capitalization of $121.42B and an annual revenue of $48.19B, supported by a workforce of 32,500 employees. These valuation and revenue figures position Bristol-Myers Squibb as a major player in the pharmaceutical landscape, reflecting significant market trust and a vast reach in delivering oncology, hematology, immunology, cardiovascular, and neuroscience therapies worldwide.
财务健康
The company reports a trailing twelve-month revenue of $48.19B with a corresponding net income of $7.05B and an EBITDA of $19.12B. The substantial gap between the $48.19B revenue and the $7.05B net income reveals a cost structure where approximately 85.4% of revenue is consumed by operating expenses, taxes, and interest before reaching the bottom line. Free cash flow stands at $11.15B, which indicates strong financial flexibility allowing the company to fund research and development or return capital to shareholders without immediate need for external financing. Profitability is supported by a gross margin of 72.6%, an operating margin of 28.2%, and a profit margin of 14.6%, each metric highlighting efficiency at different stages of the production and sales cycle. Regarding capital structure, the company holds $10.67B in cash against $47.19B in total debt, resulting in a debt-to-equity ratio of 254.98%, which suggests a highly leveraged balance sheet typical for capital-intensive pharmaceutical firms. Short-term liquidity is assessed via a current ratio of 1.25, indicating the company possesses sufficient current assets to cover its current liabilities, though the margin is relatively narrow. Management effectiveness is further illuminated by a return on equity of 40.4% and a return on assets of 10.3%, demonstrating efficient generation of profits relative to the equity invested and the total asset base utilized.
估值评估
Valuation metrics for Bristol-Myers Squibb show a trailing P/E ratio of 17.19 and a forward P/E of 9.66, where the significant difference implies that the market expects earnings to grow substantially or that current earnings are temporarily suppressed. The price-to-book ratio stands at 6.55, indicating that the market values the company at a significant premium over its net asset book value, reflecting the high value placed on its intangible assets like patents and brand equity. Alternative valuation measures include a price-to-sales ratio of 2.52 and an EV/EBITDA of 8.25, which provide context on the company's valuation relative to its sales volume and earnings power adjusted for enterprise value. Price volatility and trading range are defined by a 52-week high of $62.89 and a 52-week low of $42.52, establishing the bounds within which the stock has traded over the past year. The beta value of 0.27 indicates that the stock price exhibits low volatility relative to the broader market, moving less than half as much as the market index on average.
Growth & Income
Growth dynamics are captured by a revenue growth rate of 1.3% and an earnings growth rate of 1392.1%, suggesting that earnings are expanding at a pace vastly faster than revenue, likely due to one-time adjustments, buybacks, or specific product mix changes rather than pure top-line expansion. As a dividend payer, the company offers a dividend yield of 4.2% with a payout ratio of 72.0%, a level that must be carefully monitored given the high leverage, though the massive earnings growth provides a buffer for sustaining this payout. The divergence between modest revenue growth and explosive earnings growth highlights a period of intense earnings optimization rather than broad-based sales acceleration. Overall, the company presents a profile characterized by stable, low-volatility income generation with significant earnings expansion, supported by a high-yield dividend and a market capitalization of $121.42B.